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Oral Pathobiont Activates Anti-
Apoptotic Pathway, Promoting 
both Immune Suppression and 
Oncogenic Cell Proliferation
Pachiappan Arjunan1, Mohamed M. Meghil  1,3, Wenhu Pi2, Jinxian Xu1, Liwei Lang3, 
Ahmed El-Awady1, William Sullivan4, Mythilypriya Rajendran1, Mariana Sousa Rabelo1,5, 
Tong Wang1, Omnia K. Tawfik1, Govindarajan Kunde-Ramamoorthy6, Nagendra Singh7, 
Thangaraju Muthusamy  7, Cristiano Susin1, Yong Teng  3, Roger M. Arce  1 & 
Christopher W. Cutler  1
Chronic periodontitis (CP) is a microbial dysbiotic disease linked to increased risk of oral squamous cell 
carcinomas (OSCCs). To address the underlying mechanisms, mouse and human cell infection models 
and human biopsy samples were employed. We show that the ‘keystone’ pathogen Porphyromonas 
gingivalis, disrupts immune surveillance by generating myeloid-derived dendritic suppressor cells 
(MDDSCs) from monocytes. MDDSCs inhibit CTLs and induce FOXP3 + Tregs through an anti-apoptotic 
pathway. This pathway, involving pAKT1, pFOXO1, FOXP3, IDO1 and BIM, is activated in humans with 
CP and in mice orally infected with Mfa1 expressing P. gingivalis strains. Mechanistically, activation 
of this pathway, demonstrating FOXP3 as a direct FOXO1-target gene, was demonstrated by ChIP-
assay in human CP gingiva. Expression of oncogenic but not tumor suppressor markers is consistent 
with tumor cell proliferation demonstrated in OSCC-P. gingivalis cocultures. Importantly, FimA + P. 
gingivalis strain MFI invades OSCCs, inducing inflammatory/angiogenic/oncogenic proteins stimulating 
OSCCs proliferation through CXCR4. Inhibition of CXCR4 abolished Pg-MFI-induced OSCCs proliferation 
and reduced expression of oncogenic proteins SDF-1/CXCR4, plus pAKT1-pFOXO1. Conclusively, 
P. gingivalis, through Mfa1 and FimA fimbriae, promotes immunosuppression and oncogenic cell 
proliferation, respectively, through a two-hit receptor-ligand process involving DC-SIGN+hi/CXCR4+hi, 
activating a pAKT+hipFOXO1+hiBIM−lowFOXP3+hi and IDO+hi- driven pathway, likely to impact the 
prognosis of oral cancers in patients with periodontitis.
The Centers for Disease Control and Prevention indicates that in the U.S. nearly 50% of adults have moderate 
periodontitis, while the World Health Organization predicts 10–15% of adults are affected by advanced perio-
dontitis1. Chronic periodontitis (CP) is linked to increased risk of many systemic diseases2 including cancers of 
gastrointestinal (GI) tract3 and oral squamous cell carcinoma (OSCC)4. CP patients are at substantial risk for 
developing deadly oral cancers, 90% of which are recurrent OSCC having less than 50% survival rate5,6. It has 
been denoted that patients with CP are more susceptible to poorly differentiated OSCC than those without peri-
odontitis, thus indicating the association of periodontal disease with the development as well as advancement of 
oral cancers7,8. A recent cohort study emphasizes the role of periodontal disease in incident cancer risk among 
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postmenopausal women9. Chronic inflammation of the periodontal tissues is mainly caused by a complex inter-
action of oral pathogens in the dental biofilm. Porphyromonas gingivalis (Pg)10 is a highly influential member of 
the oral biofilm, causing a mucosal dysbiosis and disrupting immune homeostasis11 through unclear mechanisms. 
Although, chronic inflammation is generally regarded as a causal factor in carcinogenesis12, the mechanistic role 
of CP and its dysbiotic microflora13,14 in cancer risk are only now beginning to be explored15.
Dendritic cells (DCs) are professional antigen presenting cells that bridge the gap between innate and adaptive 
immunity16. On the contrary, DCs can also play a role in inducing immune suppression under specific circum-
stances. From this perspective, DCs promote tolerance rather than immunity17. The functional diversity and 
plasticity of DCs has stimulated much interest in their use for immunotherapy for cancers, autoimmune and 
infectious diseases18–20. Distinct from DCs are myeloid-derived suppressor cells (MDSCs) with at least six sub-
sets discovered so far. MDSCs in melanoma patients are Stat3high and overexpress CD80, CD83 and CD209 or 
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN)21. MDSC induc-
tion of regulatory T cells (Tregs) contributes to tumor progression, failure of DC-based immunotherapy22 and 
murine oral cancers23. A main factor in Treg induction by DCs and possibly MDSCs24 is their production of immu-
noregulatory Indoleamine 2, 3-dioxygenase (IDO) enzyme. IDO is critical for Treg function and maintenance25,26 
promoting a tolerogenic state and inducing direct T cell suppression and enhancement of local Tregs27. Tregs control 
periodontitis in mice28, but are also reported to promote disease progression and pathogen immune escape29,30.
The induction of apoptosis in host cells and in their prompt removal by phagocytes is important for main-
taining tissue homeostasis. This is particularly important for the development of an immunogenic response and 
antitumor immunity. Inhibition of apoptosis is mediated by downstream effectors of serine-threonine protein 
kinase- (Akt1) and Bcl-2 family members31. This anti-apoptotic pathway is activated in DCs by many factors 
including ligation of DC-SIGN32. DC-SIGN is a key uptake signaling receptor and immune-modulator for 
many pathogens, including Mycobacterium tuberculosis, Helicobacter pylori33, and as we have shown, fimbriated 
(Mfa1+) P. gingivalis strains34. Oral colonization with P. gingivalis leads to invasion of DCs and of their myeloid 
progenitors through the action of DC-SIGN ligand Mfa1 and TLR2/C-X-C chemokine receptor type 4 (CXCR4) 
ligand FimA. The chemokine stromal cell-derived factor 1 (SDF-1) and CXCR4 are significant markers of poor 
prognosis in many hematological malignancies35. Once phosphorylation occurs through Akt-1, the Forkhead 
box class-O (FOXO) proteins migrate from the nucleus and remain transcriptionally inactive resulting in their 
degradation or sequestration35,36. Since genes encoding pro-apoptotic molecules particularly Bcl-2 member 
Bim37 are activated by FOXO members, its inactivation by DC-SIGN ligation can disrupt immune homeostasis. 
Deletion of FOXO136,38 reduces DC functions and enhances susceptibility to periodontitis in a mouse model39. 
It was described that FOXO1 silencing enhances cell proliferation and decreases apoptosis of papillary thyroid 
carcinoma cells via Akt-FOXO1 signaling40. However, the roles of phospho-Akt1 (pAKT1) in direct regulation 
of FOXO1 in CP or oral squamous carcinoma cells have not been described. Recently, we reported that human 
monocyte-derived DCs (MoDCs) exposed to P. gingivalis promote FOXO1 gene expression41. However, the 
mechanistic role of FOXO1/pFOXO1 in regulating myeloid cell plasticity and immune homeostasis in response 
to this pathogen is unknown.
We show here through a combination of human, mouse and in-vitro studies how the dysbiotic pathogen P. 
gingivalis disrupts immune surveillance in periodontitis. Mfa1-fimbriae expressing P. gingivalis strains invade 
monocytes and promote differentiation to apoptosis resistant IDO-competent MDDSCs. These MDDSCs induce 
immune tolerance through increased FOXP3 + Treg responses. Moreover, our data show in inflamed periodontal 
tissues that FOXP3 is a direct target of pFOXO1, which is regulated by pAKT1. Combined with our evidence for 
direct induction of OSCCs proliferation by P. gingivalis, we conclude that blocking this pathway is a promising 
interventional approach to restore immune-surveillance and reduce oncogenic cell proliferation in dysbiotic con-
ditions such as periodontitis.
Results
Transcriptome and phenotype profiling of a novel P. gingivalis induced myeloid subset. We 
have previously described the ability of P. gingivalis to infect monocytes isolated from human PBMCs and induce 
their differentiation into a novel immunoregulatory myeloid cell type42, that promotes Tregs and inhibits cyto-
toxic T cells43. While this myeloid cell type functionally resembles myeloid-derived suppressor cells (MDSCs), 
which have been associated with oncogenesis22,43, these are phenotypically a distinct subtype of immature DCs 
(CD14lowCD83−CD1c+DC-SIGN+) which we provisionally call Myeloid Derived Dendritic Suppressor Cells 
(MDDSCs). Transcriptional profiling of MDDSCs reveal MDSC-mediators of immunosuppression CD15, signal 
transducer and activator of transcription-3 (STAT-3) and arginase-1 (ARG1), but not canonical MDSC markers 
CD11b, CD33, CD14 and CD16 (Fig. S1A). Flow cytometry analysis (Fig. S1B) also confirms lack of canoni-
cal MDSC markers CD16, CD33 or CD11b and HLA-DRhigh expression. MDDSCs were subjected to further 
characterization by RNAseq, TaqMan qPCR and proteomics analysis; the latter to identify downstream sign-
aling pathways. In these series of experiments, a panel of highly characterized Mfa1/FimA fimbriae deficient 
mutants that target distinct pattern recognition receptors (PRRs) on DCs (Table S1), as we have reported were 
used34,41,44–46, along with WT-P. gingivalis381 (Pg381), to infect monocytes, as well as canonical GM-CSF/IL-4 
induced MoDCs. The RNA-sequencing analysis shows functional clustergram partitioned into 5 clusters such as 
1. Angiogenic-/Oncogenic & Inflammatory markers, 2. Immunosuppression/regulation, 3. Transcription Factors, 
4. Anti-apoptosis/Cell Survival, and 5. Pro-apoptosis/Cell Death in response to Pg381 and DPG3 compared with 
uninfected control. P. gingivalis381, which expresses both Mfa1 and FimA, induced T-cell suppression factors 
programmed death-ligand-1 (PD-L1 or CD274), IL-10, adenosine A2b receptor (ADORA2B), ICOS Ligand 
(CD275) involved in recruitment of T-cells into oral mucosal tissues, and IDO1, CD80 involved in immunosup-
pressive activities of MDSCs compared with uninfected control MoDCs. Also noted were transcripts related to 
cell growth/survival regulation (STAT3, STAT5B, and FOXO1) and angiogenic/oncogenic metastasis markers 
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[vascular endothelial growth factor (VEGF)-A and CXCR4] (Fig. S2A). Intriguingly, DPG3, the fimbriae mutant 
that solely expresses Mfa1 fimbriae, and that targets DC-SIGN for uptake46 and survival through autophagy eva-
sion in DCs44 induced the greatest number of distinct genes (Fig. S2A). Preferentially upregulated were angiogen-
esis-/oncogenic-/inflammation related [VEGFA, CXCR4, AKT1, adrenomedullin (ADM), interleukin 6 (IL-6) 
and interleukin 8 (IL-8)], immunosuppressive [IDO1, CD80, IL-10, B7 homolog1 or Programmed death-ligand 1 
(B7-H1 or PD-L1/CD274)] and transcription/anti-apoptosis/DC proliferation related (STAT3, STAT5B, FOXO1 
and AKT1) genes, while pro-apoptotic (BIM, BAD and CASP8)- genes were downregulated. In addition, it’s 
worth noting that the cell proliferation and oncogenic gene AKT1, angiogenic molecule VEGF-A, immunosup-
pressive molecule IDO1, IL-10, the transcription factor STAT3 were highly upregulated (≥20 FPKM), whereas 
pro-apoptotic/cell death related genes BIM, BAD, CASP8 were down-regulated in DPG3 compared with Pg381. 
Quantitative PCR data further confirms that DPG3 considerably increased (>10-fold) the expression of CD274, 
IDO1, AKT1, VEGF, CXCR4, STAT5B, FOXO1, and survivin or baculoviral inhibitor of apoptosis repeat-con-
taining 5 (BIRC5) genes (Fig. S2B) compared with uninfected control. In contrast pro-apoptotic BIM, CASP8 
and tumor suppressors FOXO3 and LDOC1 related genes were (≥5 folds) decreased, significantly, compared 
with Pg381 and uninfected control (Fig. S2A, B). Besides, immunoblot shows the decreased expression of BIM at 
protein level in DPG3 induced MDDSCs compared with Pg381, MFI and uninfected control MoDCs (Fig. S2C). 
These data collectively delineate that DPG3 was the most potent inducer of these MDDSCs.
P. gingivalis expressing Mfa1 (DPG3) directs induction of anti-apoptotic and pAKT1-pFOXO1 
mediated oncogenic signaling pathway in MDDSCs through DC-SIGN. We next examined by 
immunoblot, protein levels of pAKT and immaturity DC marker DC-SIGN in MDDSCs induced by DPG3 
relative to Pg381 and MFI (totally lacks Mfa1) or uninfected MoDCs (Fig. 1A,B). DPG3 induces more phos-
phorylation of AKT1, relative to FimA expressing strains Pg381 and MFI (Fig. 1A,D). We posited that this 
could be promoting, not only survival of DPG3 through evasion of autophagy via DC-SIGN routing44, but also 
anti-apoptotic signaling. Since BIM, a pro-apoptotic gene controlled by FOXO1, promotes DC apoptosis37, 
we assessed relative p/tFOXO1 induction by DPG3 and Pg381 in MDDSCs by immunoblot (Fig. 1A and E). 
Interestingly, the most anti-apoptotic inducing strain DPG3, considerably induced pFOXO1 whereas BIM protein 
expression decreased compared with control MoDCs (Figs 1A,F and S2C). Then, to address the role of DC-SIGN 
in activation of this signaling pathway, HIV-gp120 was used to block DC-SIGN as we have reported34,46. By 
immunoblot we detected increased DC-SIGN receptor expression by DCs induced by DPG3 relative to Pg381 and 
MFI or uninfected control (Fig. 1A,C), whereas blocking DC-SIGN with HIV-gp120 prior to infection reduced 
DPG3 (Mfa1) mediated-induction (Fig. 1B,C). However, it is noteworthy that DC-SIGN expression was not 
altered by gp120 alone in control MoDCs (Fig. 1B) and was thus a consequence of blocking P. gingivalis entry 
and/or activation of the DC-SIGN signalosome34,46. We should emphasize that DPG3 stimulation led to AKT 
serine473 (Ser473) phosphorylation which regulated FOXO1 threonine24 (Thr24) phosphorylation and expres-
sion in the DCs (Fig. 1A). Activation of AKT activity by Ser473 phosphorylation of its expression promotes cell 
survival through FOXO1 Thr24 phosphorylation. To verify the role of AKT in this pathway, DCs were co-treated 
with gp120, which impaired DC-SIGN–mediated survival signaling (Fig. 1B,D) and pFOXO1 (Fig. 1B,E). We also 
found that gp120 abolished this pathway in P. gingivalis381-induced MDDSCs by significantly decreased expres-
sion of DC-SIGN, pAKT1 and pFOXO1 functional proteins (Fig. 1C–E), whereas the apoptotic protein BIM 
was increased (Fig. 1B,F). These data thus indicate a role of DC-SIGN in the DPG3–induced pAKT1-pFOXO1 
mediated apoptosis resistance and immunosuppressive signaling pathway in MDDSCs.
Short-term murine oral infection with P. gingivalis fimbriae mutants activate immunosuppres-
sive genes in blood and splenocytes. We next tested the ability of oral infection with P. gingivalis to 
induce this immunosuppressive pathway in gingival tissue, blood and secondary lymphoid organ, spleen of mice. 
Gene expression profiles of isolated blood (Fig. 2A) and splenocytes (Fig. 2B) of BL6 mice orally infected with 
P. gingivalis or its fimbriae deficient strains show distinct in-vivo responses depending on fimbria expression 
(Fig. S3). The strongest immunosuppressive responses were induced by Mfa1 + strain DPG3 after 12 hours of 
oral infection, including upregulation of Foxo1, Cire/Cd-209a, Cd40, Cd80 and Stat3 in blood (Figs 2A and S3B) 
and splenocytes (Fig. 2B), whereas Ido1 and Foxp3 were only induced in blood, but Bim, Foxo3 and Cd33 were 
downregulated in both. Serum IgG responses to P. gingivalis381 were also dampened by oral infection with DPG3 
(Fig. 2C). These results emphasize the key role of P. gingivalis and its Mfa1 fimbriae type in early immunosup-
pressive responses.
Oncogene Akt1 induction and immunosuppressive state in DPG3-infected mice. We fur-
ther hypothesized that oncogene Akt147 was activated locally in mice orally infected with Mfa1 + P. gingivalis. 
Immunostaining (Figs 2D-left panel, E and S4A) shows pAkt1 localized mostly at the level of sulcular epithe-
lium and subjacent connective tissue, consistent with gingival inflammation, which may lead to angiogenesis and 
oncogenesis. Also, increased pFoxo1 (Fig. 2D-middle panel: phosphorylation and nuclear exclusion of pFoxo1 
protein indicated by arrow marks, 2F and S4B-left panel) expression was noted in DPG3 and Pg381 infected 
mouse splenocytes, compared to CMC treated. It is interesting to note that Foxp3 an important immunosuppres-
sive factor in regulatory T cells (Tregs), is significantly increased in the gingiva of P. gingivalis and DPG3 infected 
mice (Fig. 2D,G and S4B-right panel), and in spleen of DPG3 and Pg381infected mice by immunoblot compared 
to uninfected CMC control. These data suggest that the fimbriae expression pattern of P. gingivalis strain type may 
play a key role in oncogenic progression and immunosuppression.
Distinct and direct induction of proliferation of oral cancer cell lines by P. gingivalis. We further 
hypothesized that activation of this pAKT-pFOXO1 signaling pathway by P. gingivalis would promote direct 
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proliferation of OSCCs in-vitro. The results show that human head and neck oral squamous carcinoma cell 
(OSCCs) lines HN6 and HN12 were stimulated to proliferate, but not by Mfa1 + DPG3, as we suspected, but by 
FimA+MFI, relative to uninfected control or E-coli-LPS stimulated, at 24, 48 and 72 hours (Fig. 3A). No prolifera-
tion was induced in the noncancerous human oral keratinocytes (hTERT HAK Clone 41) (Fig. 3B), human retinal 
pigment epithelial (ARPE) or mouse embryonic fibroblasts (MEF) cells (Fig. S5). Apoptotic cells were observed in 
Pg strain- infected ARPE cells at 48 and 72 hours, compared with uninfected control (Fig. S5). Stimulation of pro-
liferation by FimA+MFI was superior to FadA+ oncogenic Fusobacterium nucleatum48 at 48 and 72 hours. Thus 
FimA+MFI strain induced the most direct effect on proliferation of cancer epithelial cell lines. In contrast, non-
cancerous oral keratinocytes, ARPE and MEF cells were not stimulated by P. gingivalis381. Real-time quantitative 
Figure 1. DPG3 activated DC-SIGN, AKT, regulated FOXO1 phosphorylation/expression was required 
for the survival effect of DPG3 in MDDSCs. Immature monocytes isolated from human peripheral blood 
mononuclear cells (PBMCs) were infected with Pg381, DPG3 and MFI for 6 hours at 1 MOI. (A) Immunoblot 
analysis of DC-SIGN, p/tAKT, p/tFOXO1 and BIM in MDDSCs and MoDCs with GAPDH as loading control. 
Immunoblot detected increased expression of DC-SIGN, p/tAKT, p/tFOXO1 and decreased expression of 
BIM in DPG3- infected MDDSCs compared with uninfected control MoDCs. (B) DC-SIGN was blocked with 
HIV-gp120 (6ug/ml) for 30 minutes before infection. Notably, DC-SIGN expression and internalization was 
abolished by its antagonist HIV-gp120 and consequently the downstream signaling cascade also blocked as 
evident by dephosphorylated or decreased expression of pAKT (B,D), pFOXO1 (B,E) and increased expression 
of BIM (B,F). (C–F) Quantification analysis of DC-SIGN (C), and relative ratio of p/tAKT (D), p/tFOXO1 (E) 
and BIM (F) after normalized with the internal control GAPDH. Results are from one representative of three 
independent experiments. Data were analyzed by performing one-way ANOVA with Tukey’s post hoc using 
Prism GraphPad. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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PCR (qPCR) analysis at 24 hours shows > 2-fold induction of angiogenesis, oncogenic and proliferation related 
genes (CXCR4, SDF1, AKT1, FOXO1) in HN6 cells, whereas apoptosis (BIM) and tumor suppressor (FOXO3) 
related genes were down-regulated by all strains (Fig. 3C).
FimA-expressing P. gingivalis promotes OSCC proliferation via CXCR4. As FimA targets CXCR4 
on macrophages49, and is a co-receptor for the entry of specific strains of human immunodeficiency virus type I, 
we treated HN6 cells with CXCR4 inhibitor AMD3100, prior to co-culture with FimA+MFI. The results demon-
strate a marked inhibition of HN6 proliferation (Fig. 3D) and comparable with control. In contrast blocking 
DC-SIGN mediated uptake of DPG3 using HIV-gp120 did not ablate proliferation (Fig. 3D). These results eluci-
date the critical role of CXCR4 and thus possibly FimA, in promoting OSCC cell growth.
Figure 2. Oral infection of mice with P. gingivalis induces pAkt/pFoxo1/Foxp3 mediated immunosuppression. 
The gene expression profile shows differential response of blood (A) and splenocytes (B) isolated from DPG3-
infected mice (n = 3) at 12 hours compared with negative control group (n = 3; 2% CMC without bacteria). 
Total of 36 mice were sacrificed at 1, 12 and 24 hours (from groups:- 1. CMC; 2. Pg381; 3. DPG3 and 4. 
MFI), and blood (refer Fig. S3) and splenocytes were collected and genes quantified by TaqMan® array. (C) 
P. gingivalis DPG3-fimbriae mutants induce lower IgG antibody titer after 4-weeks oral infection. Sera from 
infected mice (n = 12) was collected after 4 weeks of infection with Pg381, DPG3, MFI and CMC control to 
determine total IgG titers against respective formalin-killed P. gingivalis strains, measured by ELISA. DPG3 was 
shown to induce reduced antibody titer compared to Pg381, whereas MFI induced minimal IgG. ***P < 0.001, 
ANOVA. (D) Immunofluorescence analysis (IFA) of pAkt1 protein expression in gingival interproximal papilla 
area between M1&M2, pFoxo1 and Foxp3 in spleen tissue from DPG3, Pg381 infected mice, compared with 
uninfected CMC group (refer Fig. S4). Arrow shows Foxo1 phosphorylation and nuclear exclusion of pFoxo1 
(middle panel). For independent channels refer Fig. S4. Scale bar: D 20 µm. Images are representative of three 
independent experiments. (E–G) Quantification analysis of pAkt, pFoxo1 and Foxp3 expression in DPG3 
and Pg381 compared to CMC infected mice gingiva (E) and splenocytes (F and G). (H) Immunoblot shows 
increased expression of Foxp3 in Pg381 and DPG3 infected mice splenocytes, compared with CMC. *P ≤ 0.05, 
**P ≤ 0.01.
www.nature.com/scientificreports/
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FimA activates CXCR4-mediated cellular signaling in OSCCs. Next, we tested whether the HN6 cells 
express DC-SIGN, since blocking DC-SIGN mediated uptake of DPG3 by gp120 was not able to block the pro-
liferation of OSCCs. Immunoblot analysis confirmed that HN6 cells constitutively express CXCR4 (Fig. 3E), but 
not DC-SIGN (Fig. 3F); moreover, CXCR4, but not DC-SIGN is upregulated by P. gingivalis381 (Fig. 3F). Thus, 
differential receptor expression helps to explain the distinct roles of Mfa1 and FimA fimbriae in MDDSCs versus 
epithelial cells. Nonetheless, CXCR4 upregulation was also accompanied by increased phosphorylation of AKT1 
(Ser473), pAKT1 accumulation in the cytoplasm, and translocation into the nucleus, resulting in activation of 
Figure 3. FimA+Mfa1− Pg strain MFI stimulates proliferation of Human oral squamous carcinoma cells via 
CXCR4. (A) Pg-MFI (Mfa1−/FimA+) stimulates proliferation of human head and neck OSC cell lines HN6 
and HN12, compared to uninfected cells or those incubated with E. coli-LPS, but not the noncancerous (B) 
oral keratinocytes (hTERT HAK Clone 41). For other noncancerous ARPE and MEF cells refer Fig. S5. (C) 
Wild-type Pg381, DPG3 and MFI induces expression of CXCR4, AKT1, FOXO1 and SDF1 in HN6 cells at 
24 hours, whereas decreases the expression of BIM and FOXO3, as determined by qPCR. (D) Suppression of 
MFI-stimulated cell growth by inhibiting CXCR4. MFI-stimulated HN6 growth was inhibited by the CXCR4-
antagonist AMD3100, but weakly or not by the DC-SIGN inhibitor gp120 after infected with DPG3. (E) MFI 
activates CXCR4-mediated Cellular Signaling in the direction of oncogenesis. Immunoblot analysis was used 
to detect the following proteins SDF-1/CXCR4, p/tAKT1, and p/tFOXO1 in E. coli-LPS, FadA+, Pg381, DPG3 
and MIF treated HN6 cells compared with uninfected control, but pAKT1, pFOXO1 and SDF-1/CXCR4, were 
inhibited by their respective inhibitors such as MK-2206 (MK), AS1842856 (AS) and AMD3100. (F) DC-SIGN 
was not detectable by immunoblot in HN6 cells, thus confirming role of CXCR4 in FimA+ MFI stimulation 
of proliferation. The results are presented (as the mean ± SD) from one representative of four independent 
experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
www.nature.com/scientificreports/
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pAKT1-regulated transcription, as evidenced by increased expression and its Thr24 phosphorylation of tran-
scription factors FOXO1 (Fig. 3E). The CXCR4 inhibitor AMD3100 reduced expression of oncogenic proteins 
SDF-1/CXCR4 expression, as well as pAKT1 and pFOXO1 activation (Fig. 3E), but it is interesting to note that 
the CXCR4 expression is comparable with the uninfected control. Moreover, control inhibitors of pAKT1 and 
pFOXO1, MK-2206 2HCL (MK) and AS184285 (AS), respectively, blocked activation of respective mediators 
(Fig. 3E). It is noteworthy that DPG3 also induces expression of CXCR4 in HN6 (Fig. 3E), however, the DC-SIGN 
expression was not detectable by immunoblot after exposure to Pg381and their mutant strains (Fig. 3F), thus, 
this data suggests that in addition to the receptor function of CXCR4 protein, its role as a metastasis mediator is 
only activated upon ligation by the cognate ligand, in this case, FimA. Although CXCR4 expression is higher in 
both DPG3 and MFI stimulated HN6 cells, DPG3 lacks FimA for ligation of CXCR4 leading to proliferation of 
OSCCs. Over all, these results suggest that CXCR4, provided it is ligated by FimA, is required for activation of 
the same pathway in OSCCs as in MDDSCs, namely, pAKT1-pFOXO1 pathway involved in immunosuppression 
and oncogenesis.
Systemic immunosuppressive and oncogenic state in CP patients. To determine if this immu-
nosuppressive and oncogenic pathway is active in humans with chronic periodontitis (CP), blood and gingival 
biopsy samples were obtained from CP and healthy control subjects. RNA of enriched DCs was analyzed for dif-
ferentially expressed genes in CP patients normalized to healthy controls. The genes were cross-referenced with 
gene database from RNAseq of in-vitro MoDC infection model41. Of major significance were genes specifically 
induced in MoDCs in-vitro by DPG3, namely, CD274, IDO1, FOXO1, AKT1, CD209 (DC-SIGN), CXCR4, IL-10, 
FOXP3, CCL2 (MCP-1), STAT3 and STAT5B. Many of these same genes, particularly involved in immunosup-
pression (IDO1, IL-10, CD274, ARG1 and CD80), oncogenesis (CXCR4, SDF-1, AKT1 and STAT3) were highly 
induced in ex-vivo isolated blood panDCs of CP patients (Fig. 4A), whereas SOCS3 and SOCS1 were downreg-
ulated, which could render DCs more tolerogenic. Of vital note is the gene for IDO1, which was upregulated 
5-fold relative to controls, consistent with our previous in-vitro P. gingivalis infection model43. Histopathological 
analysis of gingival tissues from representative CP subject, compared with healthy control, shows chronic inflam-
matory infiltrates consisting of lymphoid and myeloid cells in the CP connective tissues (Fig. 4B). Preferential 
induction of dysbiotic transcription factor pAKT1 in CP gingival tissues by myeloid dendritic cell subpopulation, 
as confirmed by immunofluorescence analysis (Figs 4C and S6) showing pAKT co-localization with pFOXO1 
and DC-SIGN (DC’s marker) as well as the immunosuppressive Treg protein FOXP3 co-localized with DC-SIGN, 
compared with healthy control, supporting involvement of pAKT1 in dysbiosis. Interestingly, immunoblot shows 
increased pAKT1, pFOXO1, FOXP3, IDO1 and decreased BIM proteins (involved in immunosuppressive and 
oncogenic pathway) in CP gingival tissues compared with healthy controls (Fig. 4D). These data support an 
immunosuppressive state in severe CP patients prone to the oncogenic process.
P. gingivalis and its Mfa1 fimbrial genotype increased in enriched blood DCs from CP 
patients. To identify the presence of P. gingivalis and its relative Mfa1 + fimbrial expression in CP, we ana-
lyzed mRNA from enriched blood panDCs of CP patients and healthy controls. The healthy control DCs con-
tained no detectable P. gingivalis 16 s rDNA, so we focused on CP samples. The results (Fig. 4E) show higher 
mRNA-expression of Mfa1, relative to the other fimbriae type, FimA, inside blood DCs. When considered in the 
context of immune homeostatic functions disrupted by DPG3 in-vitro (Fig. 1), in-vivo (Fig. 2) and in CP samples 
(Fig. 4), this supports Mfa1 as an important dysbiotic factor that promotes a systemic immunosuppressive and 
anti-apoptotic state. This result also suggests that Pg381 may adapt physiologically and genetically to the in vivo 
environment of CP by upregulating immunosuppressive genes.
Role of FOXO1, FOXP3 and BIM target genes in FOXO1 and AKT1 signaling in CP patients. To 
confirm the mechanistic role of AKT1 or FOXO1 in regulation of FOXO1, FOXP3 and BIM transcription in 
CP tissues in situ, we searched for evolutionarily conserved FOXO-binding sites in human FOXO1, FOXP3 and 
BIM loci. Using the rVISTA tool, we found putative FOXO1 and FOXP3 -binding sites in previously defined 
conserved noncoding sequences of FOXO1, FOXP3, and BIM promoter region (Table S4). We reiterate the 
observation of dramatically higher levels of pFOXO1 in DPG3 infection induced MDDSCs compared to control 
monocytes (Fig. 1) suggesting that FOXO1 expression is negatively regulated by PI3K–AKT signaling pathway. 
To further corroborate FOXO1 as a target for AKT1 in cells from gingival tissues of CP, we examined FOXO1 as 
well as FOXP3 and BIM expression and their nuclear localization using antibodies to FOXO1 (anti-FOXO1) or 
anti-AKT1. Chromatin Immunoprecipitation (ChIP) assays demonstrated genomic fragments containing the 
proximal FOXO1 (Fig. 4F) promoter regions in the DNA upstream of the translation start site selectively enriched 
with the pAKT1 antibody, whereas the BIM (Fig. 4H) was significantly decreased in gingival tissues. We next 
tested if FOXO1 regulates the expression of FOXP3 and BIM in cells from gingival tissues, selectively enriched 
and repressed for genomic fragments containing the region in FOXP3 (Fig. 4G) and BIM (Fig. 4H) promoters, 
respectively. This finding describes a critical role for an evolutionarily conserved AKT1 and FOXO1 binding 
elements in control of FOXO1, FOXP3 and BIM promoter activity and supports their role as target genes for 
immunosuppression and dysbiosis in CP.
Oncogenic profile confirmed in oral tissues from P. gingivalis infected CP patients. Since 
MDDSCs provide anti-apoptotic, immunosuppressive functions in-vitro and in-vivo; we further analyzed the 
genes and proteins related to oral cancer in P. gingivalis infected CP patient tissues by qPCR and immunoblot, 
respectively. The results delineate increased expression of angiogenic and oncogenic markers CXCR4, SDF-1, and 
decreased expression of tumor suppressor genes, IRF1, LDOC1, and FOXO3 in CP patient tissues (Fig. 4A). A 
surprise consequence was the similar responses observed in CP patient samples as MDDSC phenotypic markers 
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Figure 4. Enriched blood panDCs and gingival tissues of CP patients reveal immunosuppressive state. (A) 
29 genes associated with transcriptional regulation, inflammation, immunosuppression, cell proliferation, 
anti-apoptosis and other homeostatic functions were identified from the RNAseq data. Bar graphs show both 
up- (red) and down- (blue) regulation of genes (≥±2 fold) in ex-vivo isolated and panDC-enriched blood 
samples from CP patients compared to healthy controls confirmed by TaqManPCR. The overall validation data 
shows the same trend as in RNAseq analysis. (B) H&E of healthy control and CP patient’s gingival tissue. The 
arrows indicate the infiltrating cells of inflammatory responses; (20X), CT- Connective Tissue, ET- Epithelial 
Tissue. Results are representative of two experiments (n = 9/group). (C) Co-localized expression of pAKT1/
pFOXO1, pAKT1/DC-SIGN (receptor for Mfa1) and DC-SIGN/FOXP3 (arrowhead) in gingival connective 
tissue (marked in b) from CP, compared with healthy control. Images are representative of three independent 
experiments (Scale bar- 100 µm; pls refer Fig. S6 for independent channel and their quantification measurement 
of co-localization. (D) Immunoblot analysis of p/tAKT1, p/tFOXO1, FOXP3, IDO1, BIM, CXCR4 and SDF1 
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(CD16−low, CD11b−low and CD33−low) (Fig. 4A) was also consistent with the results obtained in-vitro (Fig. S1A,B). 
Interestingly, immunoblot analysis shows increased expression of oncogenic markers CXCR4 and SDF-1 in oral 
tissues of CP compared with healthy controls (Fig. 4D), thus these data demonstrate that the pathobiont P. gingi-
valis activates anti-apoptotic pathway promoting immune suppression and possibly, oncogenesis.
Discussion
We report here two distinct, though linked mechanisms activated by the oral pathobiont P. gingivalis that may 
possibly promote oral and other cancers: (a) immunosuppression through induction of MDDSCs, predomi-
nantly dependent on the DC-SIGN targeting Mfa1 fimbriae and (b) oncogenic response, predominantly through 
the CXCR4-targeting FimA fimbriae. Several recent reviews discuss the various cancers associated with CP, 
including gastrointestinal, pancreatobiliary tract50 and oral squamous cell carcinoma (OSCC)4,51,52. OSCC rep-
resents the sixth most common malignant tumor. Nearly, 90% of cancers of the upper aerodigestive tract are 
SCCs53,54. The role of oral microbiome, including P. gingivalis, Fusobacterium nucleatum (Fn), Streptococcus gor-
donii (Sg) and other species in oral, esophageal, pancreatic, gastrointestinal and colorectal cancers has also been 
described46,48,54–56. P. gingivalis promotes a mucosal dysbiosis, disrupting immune homeostasis through unclear 
mechanisms. P. gingivalis colonizes pre-malignant lesions of the esophagus57 and OSCC54 and has been called a 
keystone pathogen due to its outsized influence on the oral commensal microflora55. An invasive pathogen, P. gin-
givalis infects myeloid DCs46, endothelial cells58 and epithelial cells59 in periodontitis. P. gingivalis is able to survive 
in the host environment by evading autophagy in DCs44 and is disseminated within migratory blood DCs15. The 
DCs thus subjugated are resistant to apoptosis and are re-directed to the periphery45. The present study shows 
how immune homeostasis by this periodontal infection is disrupted, contributing to dysbiotic diseases of the 
upper11 and lower60 GI tract.
MDDSCs induced by Mfa1 + P. gingivalis share monocytic lineage with MDSCs and with conventional 
DCs. Common function-related markers in MDDSCs and MDSCs include IL-10, TGFβ and PD-L161, as well 
as STAT3, CD15 and ARG1 in human MDSCs22. A recent review highlights the importance of phenotypic and 
transcriptional-profiling to redefine the DC lineage62. As blood panDCs of CP patients contained P. gingivalis 
Mfa-1, transcriptional profiling of panDCs was performed and cross-referenced with transcripts induced by 
infection of human monocytes and mice with Mfa1 + P. gingivalis. Most notable were of genes involved in DC 
differentiation, immune regulation and regulation of apoptosis, markedly FOXO1. Examination of gingival tis-
sues of CP patients by functional genomics ChIP assay specifically links FOXO1 proteins with the DNA element 
of FOXP3, indicating that FOXP3 is a direct FOXO1 target gene in CP tissues. This is consistent with the demon-
strated ability of MDDSCs to induce Treg. The progression of CP in humans is related to over-expression of FOXP3 
and IL-1763 and with uptake of P. gingivalis by blood myeloid-derived DCs in-vivo15. In addition, the transcription 
factor STAT5B, also activated by Mfa1 + P. gingivalis strain DPG3, binds to regulatory elements in the FOXP3 
locus and may regulate FOXP3 expression. Thus, FOXO1 proteins appear to be primary regulators of MDDSC 
plasticity and Treg cell lineage and are induced by P. gingivalis infection. The production of IDO1 in chronically 
inflamed sites, as in CP64, can block Th1 and Th17 effector differentiation, T cell apoptosis and promote Tregs. 
Immature or regulatory DCs can produce IDO65 capable of biasing the immune system towards tumor growth 
support. High rates of necrotic and apoptotic cell death have been observed in IDO-KO mice after P. gingivalis 
LPS challenge compared to WT mice26. We showed that IDO was involved in both anti-apoptotic and immune 
suppressive response of MDDSCs. In addition, we have also shown increased expression of immunosuppres-
sive cytokines IL-10, TGFβ66, immunosuppressive molecule PD-L167,68 and Survivin (BIRC5)69, which influence 
tumor progression in many types of cancers. Strikingly, we found that in CP patients, there was increased expres-
sion of immunosuppressive, angiogenic and oncogenic markers, and decreased expression of tumor suppressors 
in the gingiva at mRNA and protein level. Another interesting finding of this study was increased expression of 
Mfa1 at mRNA level in CP patient blood panDCs, which might be one of the main roles of Pg381 dissemination, 
wherein the bacterium adapts physiologically or genetically to their local environment.
Our results show a key role for DC-SIGN in P. gingivalis Mfa1-mediated activation of STAT3, which phospho-
rylates AKT1 (pAKT1) for full activation. Phospho-AKT1 suppresses BIM, promoting apoptosis resistance and 
monocyte differentiation into MDDSCs. The expression of active forms of FOXO family members in dividing 
cells promote cell cycle arrest at the G1/S boundary, which is a significant cellular mechanism by which FOXO 
promotes tumor suppression70,71. Phospho-AKT1 in turn phosphorylates and inactivates FOXO1 which further 
suppress BIM, a key FOXO target gene that mediates the ability of FOXO to induce cell death72. It is interest-
ing to note that AKT-FOXO1 regulates the BIM and transcriptionally inactivates FOXO1 (pFOXO1) leaving no 
opportunity to bind with BIM to subsequently mediate apoptosis upon the persistent stimulation of Pg strains. 
Phosphorylated FOXO1 also regulates FOXP3 expression through its feedback regulatory loop mechanism as 
per the consistent and continuous stimulation of Pg strains in MDDSCs, to promote apoptosis resistance and 
immunosuppression. This pathway (DC-SIGN-pAKT1-pFOXO1-BIRC5-STAT3-IDO1-FOXP3) culminates in 
in gingival tissue of CP compared with healthy control. (E) Mfa1 and FimA mRNA in ex-vivo isolated panDCs 
from CP patients and Healthy control and normalized with the internal control. (F–H) Regulation of FOXO1, 
FOXP3, BIM transcription by FOXO1A or pAKT1. Immunoprecipitation of chromatin from the human 
FOXO1 (F), FOXP3 (G) and BIM (H) locus in mixed immune cell population from gingival tissues of CP 
and healthy control with anti-pAKT1 or anti-FOXO1A, followed by qPCR analysis of immunoprecipitants; 
results are presented relative to input by immunoprecipitation with isotype-matched control antibody. Data are 
representative of six independent experiments. *P ≤ 0.05, **P ≤ 0.01.
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MDDSC differentiation, Tregs activation and IDO-mediated immunosuppression, which may regulate cellular 
processes leading to immune escape.
We have also elucidated here an oncogenic mechanism whereby P. gingivalis activates OSCCs and have iden-
tified the molecular target. We have shown increased expression of metastasis markers CXCR4, SDF-173,74 and 
decreased tumor suppressor molecules LDOC1 and FOXO3, induction of oncogenes and promotion of tumor 
growth. Immunoblot analysis further confirmed increased expression of CXCR4 and SDF-1 in oral tissues of CP 
compared with healthy controls. Further, strain MFI (FimA+Mfa1−Pgingivalis) stimulates significant proliferation 
of CXCR4-expressing OSC (HN6, HN12) cells, but not those of noncancerous cells (oral keratinocytes, ARPE and 
MEF), which indicate that the interactions between FimA and CXCR4 play a primary role in promoting OSCCs 
tumor growth through the pAKT1-pFOXO1 dependent pathway(s). In addition, the available evidence indicates 
that the broad somatic deletion of FOXO1/3/4 in mice results in thymic lymphomas and hemangiomas75, specify-
ing that the FOXO family functions as a tumor suppressor in mice70. Interestingly, we found increased expression 
of pFOXO1 (transcriptionally inactive) and decreased expression of FOXO3 in in-vitro, in-vivo and ex-vivo sam-
ples, thus supporting the findings that FOXO family members can promote tumor progression.
In conclusion, our study supports a novel apoptosis resistant pathway (Fig. 5) that promotes both immuno-
suppression and oncogenesis, with the common factor being infection with the oral pathobiont P. gingivalis. This 
pathway, as activated in CP patients, and in mice orally infected with P. gingivalis is a common pathway involved 
in oncogenesis. Thus, our results collectively support a two-hit process, involving Mfa1-fimbriae-DC-SIGN 
mediated evasion of immune response, and FimA-CXCR4 mediated inflammation and cancer develop-
ment. Manipulation of this pathway may be therapeutically beneficial for patients in the management of 
dysbiosis-related immunological disorders as in chronic periodontitis and in preventing cancer development.
Materials and Methods
Antibodies and reagents. Anti-human CD4+, CD8+, CD11b, CD15, CD16, CD33, HLA-ABC and 
HLA-DR was procured from eBioscience. CD83, CD14, CD209 and CD1c were from eBioscience & Miltenyi 
Biotech. Anti-FOXO1 mAb (C29H4), Anti-rabbit IgG-HRP and Rabbit (DA1E) isotype control were from Cell 
signaling. Anti-Bim pAb (PA5–20089) and β-actin (MA1-91399) were obtained from Thermo Scientific. Anti-
IDO1 was from LSBio LifeSpan BioSciences. Mouse anti-Akt1 (558316), HRP goat anti-mouse IgG (554002) and 
Rabbit polyclonal IgG (27478) were from BD Pharmingen. Mouse monoclonal SDF-1 (P-159X) antibody (sc-
74271) was from Santa Cruz Biotechnology, Inc. The goat anti-mouse IgG H&L (HRP), Anti-CXCR4 (ab124824) 
Figure 5. Model of immune homeostasis disruption and dysbiosis by P. gingivalis. DC-SIGN - TLR2/
CXCR4 crosstalk activated by ligation via P. gingivalis Mfa1 - FimA, respectively, activates STAT3, resulting 
in downstream AKT1 activation that phosphorylates and inactivates FOXO1. Direct suppression of apoptotic 
activity through BIM also occurs. DC-SIGN routes P. gingivalis into non-autophagosomal compartments 
where they survive. Upon phosphorylation by AKT1 the FOXO proteins are excluded from the nucleus and 
are sequestered or degraded. FOXO inactivation contributes to extended cell survival as FOXO members 
activate genes encoding pro-apoptotic molecules including Bcl-2-member BIM. The resultant MDDSCs are 
highly resistant to apoptosis and IDO-1 competent, traveling to local and distant sites bearing the bacteria and 
promoting immunosuppression through induced-Tregs (FOXP3). In addition to the immunosuppressive route 
through DC-SIGN by DPG3 (Mfa1), \FimA (MFI) leads the direct oncogenesis route through CXCR4.
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and anti-FOXP3 pAb (ab10563) were procured from Abcam. Sheep anti-mouse IgG (whole molecule, A3563) 
was from Sigma Aldrich. The antagonists for AKT1 (MK-2206 2HCl) and FOXO1 (AS1842856) were from 
Selleckchem and Calbiochem, respectively.
Generation and phenotypic characterization of MoDCs. The conventional MoDCs were gener-
ated in-vitro as described elsewhere41 with minor modifications. Briefly, Human monocytes were isolated from 
mononuclear fractions of peripheral human blood by negative selection (EasySep™ Human Monocyte Isolation 
Kit, STEMCELL Technologies Inc. Vancouver, Canada). Cells were seeded in the presence of granulocyte–mac-
rophage colony-stimulating factor (GM-CSF)/interleukin-4 (IL-4) (1000-unit ml−1) (Gemini Bio-Products, West 
Sacramento, CA, USA) at a concentration of 3–4 × 105 cells ml−1 in RPMI 1640 (HyClone Laboratories, Logan, 
Utah, USA) containing 10% heat inactivated FBS (Atlanta Biologicals, Flowery Branch, GA, USA) and antibiotic/
antimycotic (HyClone, Logan, UT, USA) for 5–6 days. Fresh medium treated with GM-CSF and IL-4 was used 
every other day for cultured cells. Flow cytometry analyses were carried out to verify the immature DC phenotype 
(CD1a+CD83−CD14−DC-SIGN+)15,34,44–46.
Flow cytometry. Flow cytometry gates were chosen using suspension cell forward and side scatter charac-
teristics as described34,46. Briefly, non-adherent MoDCs typically fall within FSC-h 300–600 and SSC-h 100–200 
(x1000). Undifferentiated monocytes, lymphocyte carry-over, and debris were excluded from MoDC analysis. 
Monocytes displayed 95–99% differentiation into MoDCs by day 5 as described above. Monocytes were immedi-
ately infected with all isogenic P. gingivalis mutants (DPG3, MFI, MFB) and wild type at 1 MOI44 and incubated 
for 12 hours to generate MDDSCs. DC-SIGN+CD1c+ cells were chosen for analysis of MDDSCs, CD4+ cells for 
analysis of effector subsets, and CD8+ for analysis of CTLs. For statistical analyses, all experimental samples were 
compared to each other using ANOVA on the means from at least three independent flow experiments using 
GraphPad Prism6.
Bacterial culture, labeling, and MoDCs infection. Wild-type P. gingivalis381 (Pg381), which expresses 
minor (Mfa1) and major (FimA) fimbriae, isogenic major fimbria-deficient mutant Pg-DPG3 (DPG3), which 
expresses only the minor fimbriae (Mfa1+/FimA−), the isogenic minor fimbria-deficient mutant Pg-MFI (MFI), 
which expresses only the major fimbriae (Mfa1−/FimA+) and the double fimbriae mutant/naked (Mfa1−/FimA−) 
Pg-MFB (MFB) were maintained anaerobically (10% H2, 10% CO2 and 80% N2) in a Coy Laboratory vinyl anaer-
obic system glove box at 37 °C in Difco anaerobe broth MIC41. Erythromycin (5 µg/ml) and tetracycline (2 µg/ml) 
were added as per the selection requirements of the strains44,76. The MoDC were pulsed with P. gingivalis strains 
at multiplicity of infection (MOI) = 1 for 12 hours. The low MOI values were used to mimic a natural blood mDC 
infection observed in CP patients15 as well as to avoid overwhelming the host response.
RNA sequencing and functional genomics analysis. RNA-sequencing and bioinformatics analysis was 
performed as we described previously41. We have made further analysis for functional cluster, particularly FimA-/
Mfa1+ mutant strain DPG3 due to its greater virulence and Pg381 (since it expresses both FimA+/Mfa1+) in 
DCs relative to other mutants compared with uninfected control and MFB. In brief, each comparison, a gene is 
defined as differentially expressed using a fold change of ≥±2, average Fragments Per Kilobase of transcript per 
Million mapped reads (FPKM) ≥ 5 and P-value ≤ 0.01. Median FPKM values are used, if a gene has multiple iso-
forms. Clustering and visualization of differentially expressed transcripts as heatmaps were generated using heat-
maps2 for 27 filtered GO terms and annotated genes. The functionality of the selected genes was confirmed by 
qPCR, Immunofluorescence, Immunoblot and chromatin immunoprecipitation (ChiP) assays. Gene Expression 
Omnibus (GEO) accession ID #: GSE67141.
Oral infection with Pg381 and fimbriae mutants in acute and chronic murine model of CP. All 
mice had C57BL/6 backgrounds were purchased from Jackson (Bar Harbor, ME). To determine the immunob-
iological consequences of oral infection with Pg381 and fimbriae mutants (DPG3, MFI and MFB) in-vivo (for 
both acute & chronic), we orally-infected B6 mice (n = 36) with these strains and performed gene expression 
profiles of isolated blood and splenocytes. Mice were fed a normal chow diet. Six-week old male mice were treated 
with a 10-day regimen of oral antibiotics (sulfamethoxazole/trimethoprim suspension 48 mg/mL) to allow for P. 
gingivalis colonization. Mice were challenged by oral application of vehicle (2% carboxymethylcellulose-CMC 
in PBS) or the P. gingivalis strains (1 × 109 Colony Forming Units - CFU) at the buccal surface of the maxillary 
vestibule 5 times a week for 3 weeks as described77. The isogenic fimbriae deficient mutants (Table S1) were main-
tained under proper antibiotic presence to maintain mutant traits as described earlier44,76,78,79. Liquid cultures 
were maintained until mid to late log phase. Bacteria were washed/re-suspended in PBS. 1:10 dilution of the 
culture and matched to an optical density of 1.0 at 660 nm (O.D. 660 = 1 × 109 CFU/ml). 2% CMC was added 
slowly to the bacterial suspension while vortexing to avoid clumping. Purity of the cultures was verified by Gram 
stain before introducing bacteria into animals. Mice were then sacrificed at 1, 12 and 24 hours, and then blood 
and spleens were collected for RNA isolation (Qiagen). After 4 weeks of chronic infection, mice were sacrificed 
and mandibles (with attached gingiva) were harvested and fixed in 4% PFA. After 3 days, samples were decalcified 
with EDTA 14% solution for 3 weeks, then embedded in paraffin and processed for H&E and immunostaining.
Antibody Analysis. We next determined differences in anti-P. gingivalis antibody titers in BL6 mice (n = 12) 
after oral infection using standard enzyme-linked immunosorbent assay (ELISA) protocol. Briefly, diluted 
mice sera (1:100) were reacted with the bacterial antigen for 2 hours, then washed and labeled with a second-
ary antibody goat anti-mouse IgG conjugated to alkaline phosphatase (1:5000). Assays were developed with 
p-nitrophenolphosphate and reactions were terminated by the addition of 3 M NaOH and the optical density 
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(OD) was measured at OD405 nm using a BioRad Microplate Reader. Mice were monitored twice a week for clin-
ical symptoms and general health status.
Cell Proliferation and Inhibitory Assay. Cell proliferation assay was performed as described48 with a 
few modifications, briefly, human head and neck oral squamous cell carcinoma (OSCCs) derived cell lines, HN6 
and HN12 (a gift from Dr. Yeudall AW, Department of Oral Biology, AU, Augusta, GA, USA) were cultured as 
described80 and seeded in 6-well plates at 1–5 × 105 cells per well in the growth medium. Cells were uninfected or 
incubated with DPG3, MFI, FadA+ and LPS (100 ng/ml) (as positive controls) or inhibitors added at the concen-
tration of AMD3100 (50 nM), MK-2206 (2 µM), AS1842856 (50 nM), gp120 (6 µg/ml) prior to co-culture with P. 
gingivalis at MOI = 1. The concentrations of inhibitors (CXCR4 inhibitor AMD3100; AKT inhibitor MK-2206; 
FOXO1 inhibitor AS1842856) selected based on the IC50 value according to the manufacturer’s instruction. Cell 
numbers were counted at 0, 24, 48 and 72 hours using a hemocytometer. Human tonsillar keratinocytes hTERT 
HAK Clone 41 (a gift from Dr. A. Klingelhutz and Dr. J. Lee, U. Iowa, Iowa City, IA, USA81 were cultured in KSFM 
with 0.2 ng/ml epidermal growth factor (EGF) and 30 μg/ml bovine pituitary extract. Previous studies showed 
that these telomerase-immortalized keratinocytes (hitherto labeled ‘tertAd7cl41’) were functionally similar to 
primary oral keratinocytes82. The proliferation assay done as described above. Each experiment was performed 
in triplicate and repeated thrice.
Gingival biopsies and blood collection from clinically healthy subjects and CP patients. The 
study was conducted between December 2013 and May 2016 in full accordance with the Helsinki Declaration 
of 1975, as revised in 2000. All the patients were recruited from the School of Dentistry, University of São Paulo 
and Dental College of Georgia AU. A detailed medical and dental history was obtained from all patients. All 
volunteers received full mouth periodontal clinical examination performed at six sites per tooth (excluding third 
molars). CP subjects with moderate to severe disease, determined by exhibition of the following: probing depth 
of >4 mm, attachment loss of >3 mm, bleeding on probing, and alveolar bone crest >3 mm from the cemen-
toenamel junction. Gingival tissue biopsy and blood samples from CP patients (n = 24) and healthy controls 
(n = 25) were collected. We have previously reported our biopsy technique to obtain oral lymphoid foci from the 
interdental papilla without removing buccal and lingual epithelium at the deepest bleeding site83,84. These tissues 
were cryosectioned in OCT for H&E and immunofluorescence analysis by confocal microscopy. Blood was also 
collected for transcriptome and DC subset analyses as described above.
TaqMan-Array and SYBR-Green qPCR Assays. Analysis of gene expression in MDDSCs induced by 
Pg381, DPG3, MFI, and MFB, MoDCs and monocytes was performed using RT-PCR. Total RNA was isolated 
using RNeasy kit from three groups such as (1) In-vitro control and P. gingivalis strains at 1 MOI infected mono-
cytes were cultured for 6 hours, and day 6 MoDCs; (2) In-vivo mice blood and spleens at 1, 12 and 24 hours; 
and (3) Ex-vivo human blood panDCs isolated from healthy control and chronic periodontitis patients. Human 
blood DCs were negatively selected from PBMCs using panDC pre-enrichment kit (Robosep, Stem cell technol-
ogies). The isolation was performed two times to remove non-DCs. The purity of enriched DCs was 70–80%. 
Complementary DNA was synthesized from 1.1 μg RNA through a reverse-transcription reaction (Applied 
Biosystems). Real-time quantitative PCR (RT-qPCR) was performed on TaqMan array fast plates as well as recon-
firmed with SYBR green methods for selected genes (PCR primers are listed in Tables S2 & S3). The calculations 
for fold regulation used the 2−ΔΔCt method as described in our previous report41. 18SrRNA, HPRT1 and GAPDH 
were used as internal controls.
Immunofluorescence Assay (IFA). IFA was performed for paraffin embedded tissues. Briefly, the paraf-
fin embedded tissues from mice (CMC, Pg381 and DPG3 oral infected CP model) and human (healthy and CP 
patients) were rehydrated and antigen retrieved. After blocking with permeabilization buffer and 2% BSA, slides 
were then incubated with primary antibodies followed by respective secondary antibodies. Slides were mounted 
with prolong diamond anti-fading mounting medium (Invitrogen). Images were acquired with a Zeiss LSM510 
Inverted Meta scanning confocal microscope. For quantitative analysis, four fields were selected randomly and 
total cells in the field were manually counted based on their expression of the target proteins.
Immunoblot and Receptors Blockade Assays. Immature MoDC were infected with WT-Pg381, DPG3 
and MFI for 6 hours at 1 MOI. DC-SIGN was blocked with GP120 (6ug/ml) for 30 minutes before infection. 
Likewise, OSCCs were infected with Pg381, DPG3, MFI, FadA+ at MOI = 1 and LPS (100 ng/ml) (both FadA+ 
and LPS used as positive controls). CXCR4, pAKT, pFOXO1 and DC-SIGN were blocked with their respective 
antagonist (inhibitors) at the concentration of AMD3100 (50 nM), MK-2206 (2 µM), AS1842856 (50 nM), and 
gp120 (6 µg/ml). The concentrations of inhibitors were selected based on the IC50 value as per the manufacturer’s 
instruction. Whole-cell lysates were prepared from both MoDCs and OSCCs cultures by centrifuging and wash-
ing the pellet with ice-cold PBS. The gingival tissue used for this study was obtained from chronic periodontitis 
(CP) subjects (generalized severe) and healthy adult controls as previously described83. Proteins from human 
gingival tissues, mouse spleen and the cells were extracted by adding ice-cold Radioimmunoprecipitation assay 
(RIPA) buffer (Abcam) supplemented by protease inhibitor cocktail (Cell signaling). The cell lysates were centri-
fuged at 12,000 × g for 10 min at 4 °C. Samples were normalized to the amount of total protein in the supernatant 
using Pierce™ BCA Protein Assay Kit (ThermoFisher). Protein aliquots (30 μg) were separated by size on 4–15% 
Mini-PROTEAN TGX stain-free precast gels (Bio-Rad Laboratories, Inc.) and transferred to Immobilon (PVDF) 
membrane (EMD Millipore). Nonspecific binding sites were blocked by incubation in 1 × TBS-T (0.2 m Tris, 
0.14 m NaCl, 0.1% Tween 20) containing 5% non-fat milk for 1 hour at room temperature, followed by incu-
bation overnight at 4 °C with 1:1000 dilution of primary antibodies (Akt, p-Akt, FOXO1, p-FOXO1, DC-SIGN 
(CD209), and GAPDH) in 1 × TBS-T containing 5% non-fat milk. After membranes were washed three times in 
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1 × TBS-T (10 min each at room temperature), horseradish peroxidase-conjugated secondary antibody was added 
at a 1:2000 dilution and incubated for 1 hour at room temperature. After three more washes with 1 × TBS-T, the 
immunoreactive peptide was detected by Western Lightning ECL Pro Chemiluminescent reagent (PerkinElmer, 
Inc) and imaged using ChemiDoc™ MP Imaging System (Laboratories, Inc.). Data were analyzed by performing 
one-way ANOVA with Tukey’s post hoc using Prism GraphPad.
Chromatin Immunoprecipitation (ChIP). ChIP analyses were done as described36. Briefly, once the uni-
cellular suspension was obtained from the gingival tissues of CP patients and healthy subjects, cells (5 × 106) 
were fixed for 10 min at 25 °C with 10% formaldehyde. After incubation, glycine was added to a final concen-
tration of 0.125 M to ‘quench’ the formaldehyde. Cells were pelleted, washed twice with ice-cold PBS and lysed. 
The lysates were pelleted, re-suspended and sonicated to reduce DNA length to 300–500 base pairs. Chromatin 
prepared (#D5210, Zymo Research Corporation, CA) from CP patients and healthy control gingival tissue and 
cells were pre-cleared for 1 hour with protein Ultralink A/G agarose beads (Pierce, #88803) and then was incu-
bated overnight with 2 µg ChIP grade anti-AKT1 (MA5–14898; ThermoFisher), or anti-FOXO1A (ab39670; 
Abcam), or control rabbit immunoglobulin (2729; Cell Signaling), and one without antibody as the input. Particle 
Concentrator (#123.21D, Invitrogen), washed, and eluted in 100 µl of 0.1 M NaHCO3 and 1% SDS elution buffer. 
The eluted and input chromatins were incubated at 65 °C (for 3 hours) to reverse the crosslinking. After diges-
tion with proteinase K, the ChIP and input DNA were purified (using Chip DNA Clean & Concentrator Kit, 
#D5205 Zymo Research) and analyzed by quantitative PCR using site-specific primers binding of AKT1 with the 
co-factors to the FOXO1 and FOXO1 to the FOXP3 and BIM locus (Table S4).
Ethical approval and informed consent. The Human Assurance Committee (HAC) at the Augusta 
University approved this protocol involving human cells as human subject exempt, due to the use of anonymized 
peripheral blood samples for monocytes. The study protocol and informed written consent form obtained from 
all subjects were reviewed and approved by the School of Dentistry Ethics Committee, University of São Paulo, 
Brazil (658.998/CEP), and the Augusta University IRB (831204–3). All procedures involving mice were reviewed 
and approved by the Augusta University Institutional Animal Care and Use Committee (IACUC ID: # 2013-
0586)/ethics committee and were performed in accordance with the approved guidelines and regulations.
Data Availability
The datasets generated and analyzed during the current study are available from the corresponding authors on 
reasonable request.
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